Autopsy report · NCT05509582

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

“No responders in parent protocol 000758; this follow-on protocol not activated and PI leaving NIH”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Sponsor type

US National Institutes of Health

Conditions

Immune Mediated Anemia; Immune Mediated Thrombocytopenia; Chronic GVHD

Interventions

fostamatinib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• EXCOR® Pediatric VAD Anticoagulation IDE
  “PI withdrew protocol” (58% match in meaning)
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
  “Other - Protocol moved to Disapproved” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.